S&P 500   4,241.78 (-1.09%)
DOW   33,143.80 (-0.87%)
QQQ   357.52 (-1.04%)
AAPL   172.18 (-0.90%)
MSFT   318.38 (-1.06%)
META   303.87 (-0.96%)
GOOGL   133.15 (-0.76%)
AMZN   126.23 (-2.49%)
TSLA   247.52 (-1.62%)
NVDA   446.65 (-0.26%)
NIO   8.57 (-2.50%)
BABA   83.97 (-2.96%)
AMD   102.23 (-1.01%)
T   14.67 (+0.00%)
F   12.11 (-1.62%)
MU   68.83 (+1.28%)
CGC   0.69 (-6.92%)
GE   108.67 (-0.11%)
DIS   80.87 (-0.98%)
AMC   8.12 (-0.37%)
PFE   33.88 (-0.18%)
PYPL   58.11 (-0.77%)
NFLX   385.92 (+1.47%)
S&P 500   4,241.78 (-1.09%)
DOW   33,143.80 (-0.87%)
QQQ   357.52 (-1.04%)
AAPL   172.18 (-0.90%)
MSFT   318.38 (-1.06%)
META   303.87 (-0.96%)
GOOGL   133.15 (-0.76%)
AMZN   126.23 (-2.49%)
TSLA   247.52 (-1.62%)
NVDA   446.65 (-0.26%)
NIO   8.57 (-2.50%)
BABA   83.97 (-2.96%)
AMD   102.23 (-1.01%)
T   14.67 (+0.00%)
F   12.11 (-1.62%)
MU   68.83 (+1.28%)
CGC   0.69 (-6.92%)
GE   108.67 (-0.11%)
DIS   80.87 (-0.98%)
AMC   8.12 (-0.37%)
PFE   33.88 (-0.18%)
PYPL   58.11 (-0.77%)
NFLX   385.92 (+1.47%)
S&P 500   4,241.78 (-1.09%)
DOW   33,143.80 (-0.87%)
QQQ   357.52 (-1.04%)
AAPL   172.18 (-0.90%)
MSFT   318.38 (-1.06%)
META   303.87 (-0.96%)
GOOGL   133.15 (-0.76%)
AMZN   126.23 (-2.49%)
TSLA   247.52 (-1.62%)
NVDA   446.65 (-0.26%)
NIO   8.57 (-2.50%)
BABA   83.97 (-2.96%)
AMD   102.23 (-1.01%)
T   14.67 (+0.00%)
F   12.11 (-1.62%)
MU   68.83 (+1.28%)
CGC   0.69 (-6.92%)
GE   108.67 (-0.11%)
DIS   80.87 (-0.98%)
AMC   8.12 (-0.37%)
PFE   33.88 (-0.18%)
PYPL   58.11 (-0.77%)
NFLX   385.92 (+1.47%)
S&P 500   4,241.78 (-1.09%)
DOW   33,143.80 (-0.87%)
QQQ   357.52 (-1.04%)
AAPL   172.18 (-0.90%)
MSFT   318.38 (-1.06%)
META   303.87 (-0.96%)
GOOGL   133.15 (-0.76%)
AMZN   126.23 (-2.49%)
TSLA   247.52 (-1.62%)
NVDA   446.65 (-0.26%)
NIO   8.57 (-2.50%)
BABA   83.97 (-2.96%)
AMD   102.23 (-1.01%)
T   14.67 (+0.00%)
F   12.11 (-1.62%)
MU   68.83 (+1.28%)
CGC   0.69 (-6.92%)
GE   108.67 (-0.11%)
DIS   80.87 (-0.98%)
AMC   8.12 (-0.37%)
PFE   33.88 (-0.18%)
PYPL   58.11 (-0.77%)
NFLX   385.92 (+1.47%)
NASDAQ:BIOC

Biocept (BIOC) Stock Forecast, Price & News

$1.12
+0.02 (+1.94%)
(As of 10:10 AM ET)
Compare
Today's Range
$1.11
$1.12
50-Day Range
$0.82
$1.67
52-Week Range
$0.80
$28.26
Volume
7,688 shs
Average Volume
708,642 shs
Market Capitalization
$2.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

BIOC stock logo

About Biocept (NASDAQ:BIOC) Stock

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

BIOC Price History

BIOC Stock News Headlines

Biocept (NASDAQ:BIOC) Cut to Sell at StockNews.com
Biocept, Inc. (NASDAQ:BIOC) Short Interest Update
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
Maxim Group Remains a Hold on Biocept (BIOC)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
Biocept (BIOC) Gets a Hold from Maxim Group
Biocept Reports Second Quarter 2023 Financial Results
See More Headlines
Receive BIOC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biocept and its competitors with MarketBeat's FREE daily newsletter.

BIOC Company Calendar

Last Earnings
8/14/2023
Today
10/03/2023
Next Earnings (Estimated)
11/20/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BIOC
Employees
50
Year Founded
1993

Profitability

Net Income
$-32,090,000.00
Pretax Margin
-564.02%

Debt

Sales & Book Value

Annual Sales
$25.86 million
Book Value
$15.60 per share

Miscellaneous

Free Float
2,584,000
Market Cap
$2.89 million
Optionable
Optionable
Beta
0.69

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Antonino Morales (Age 67)
    CEO, Pres & Director
    Comp: $439.43k
  • Mr. Darrell Taylor Esq. (Age 58)
    Chief Legal Officer, Chief Compliance Officer, Corp. Sec. & Registered In-House Counsel
    Comp: $432.27k
  • Dr. Soon Kap Hahn Ph.D.
    Founder
  • Mr. Rob Walsh
    VP & Controller
  • Dr. Philippe J. Marchand Ph.D. (Age 60)
    Chief Operating Officer
  • Mr. Pavel Tsinberg
    Director of Technology Devel.
  • Mr. David S. Moskowitz R.Ph.
    MBA, VP of Strategy & Corp. Communications
  • Dr. Veena M. Singh (Age 48)
    Sr. Medical Director













BIOC Stock - Frequently Asked Questions

Should I buy or sell Biocept stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BIOC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIOC, but not buy additional shares or sell existing shares.
View BIOC analyst ratings
or view top-rated stocks.

How have BIOC shares performed in 2023?

Biocept's stock was trading at $15.90 at the beginning of 2023. Since then, BIOC shares have decreased by 93.1% and is now trading at $1.10.
View the best growth stocks for 2023 here
.

Are investors shorting Biocept?

Biocept saw a increase in short interest in September. As of September 15th, there was short interest totaling 610,600 shares, an increase of 3,692.5% from the August 31st total of 16,100 shares. Based on an average trading volume of 1,880,000 shares, the short-interest ratio is presently 0.3 days. Currently, 23.3% of the company's stock are sold short.
View Biocept's Short Interest
.

When is Biocept's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 20th 2023.
View our BIOC earnings forecast
.

How were Biocept's earnings last quarter?

Biocept, Inc. (NASDAQ:BIOC) posted its quarterly earnings results on Monday, August, 14th. The medical research company reported ($3.50) EPS for the quarter. The medical research company had revenue of $0.59 million for the quarter.

When did Biocept's stock split?

Biocept shares reverse split on the morning of Wednesday, May 17th 2023. The 1-30 reverse split was announced on Wednesday, May 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What is Michael Nall's approval rating as Biocept's CEO?

4 employees have rated Biocept Chief Executive Officer Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among the company's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at Biocept to a friend.

What other stocks do shareholders of Biocept own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST).

What is Biocept's stock symbol?

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

How do I buy shares of Biocept?

Shares of BIOC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biocept's stock price today?

One share of BIOC stock can currently be purchased for approximately $1.10.

How much money does Biocept make?

Biocept (NASDAQ:BIOC) has a market capitalization of $2.89 million and generates $25.86 million in revenue each year. The medical research company earns $-32,090,000.00 in net income (profit) each year or ($58.4549) on an earnings per share basis.

How can I contact Biocept?

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The official website for the company is www.biocept.com. The medical research company can be reached via phone at (858) 320-8200, via email at ir@biocept.com, or via fax at 858-320-8225.

This page (NASDAQ:BIOC) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -